Quanterix Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 450

Employees

  • Stock Symbol
  • QTRX

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $2.03
  • (As of Thursday Closing)

Quanterix General Information

Description

Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.

Contact Information

Formerly Known As
Digital Genomics
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 900 Middlesex Turnpike
  • Building 1
  • Billerica, MA 01821
  • United States
+1 (617)
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 900 Middlesex Turnpike
  • Building 1
  • Billerica, MA 01821
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Quanterix Stock Performance

As of 19-Nov-2026, Quanterix’s stock price is $2.03. Its current market cap is $96.4M with 47.5M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.03 $2.07 $1.76 - $8.77 $96.4M 47.5M 710K -$2.36

Quanterix Financials Summary

As of 30-Sep-2026, Quanterix has a trailing 12-month revenue of $148M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 115,315 202,392 154,482 748,954
Revenue 147,907 138,654 135,436 121,139
EBITDA (86,612) (101,913) (44,396) (35,184)
Net Income (111,185) (107,150) (38,531) (28,354)
Total Assets 300,437 418,766 406,533 428,567
Total Debt 31,362 37,239 37,371 41,464
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Quanterix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Quanterix‘s full profile, request access.

Request a free trial

Quanterix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra
Diagnostic Equipment
Billerica, MA
450 As of 2025

Redwood City, CA
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Quanterix Competitors (9)

One of Quanterix’s 9 competitors is Seer, a Formerly VC-backed company based in Redwood City, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seer Formerly VC-backed Redwood City, CA
Revvity Corporation Waltham, MA
Bio-Rad Laboratories Corporation Hercules, CA
Siemens Healthineers Corporation Forchheim, Germany
Meridian Bioscience Private Equity-Backed Cincinnati, OH
You’re viewing 5 of 9 competitors. Get the full list »

Quanterix Patents

Quanterix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026006441-A1 Systems and methods for improving biomarker detection results using multiple biomarkers Pending 26-Jun-2024
WO-2026006441-A8 Systems and methods for improving biomarker detection results using multiple biomarkers Pending 26-Jun-2024
AU-2025232769-A1 Systems and methods for biological sample imaging and analysis Pending 06-Mar-2024
WO-2025188900-A1 Systems and methods for biological sample imaging and analysis Pending 06-Mar-2024
WO-2025188900-A8 Systems and methods for biological sample imaging and analysis Pending 06-Mar-2024 G01N21/6458
To view Quanterix’s complete patent history, request access »

Quanterix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Quanterix Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Quanterix‘s full profile, request access.

Request a free trial

Quanterix Acquisitions (4)

Quanterix’s most recent deal was a Merger/Acquisition with Akoya Biosciences for . The deal was made on 08-Jul-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Akoya Biosciences 08-Jul-2025 Merger/Acquisition Other Pharmaceuticals and Biotechnology
Emission 08-Jan-2025 Merger/Acquisition Other Commercial Products
UmanDiagnostics 01-Aug-2019 Merger/Acquisition Diagnostic Equipment
Aushon BioSystems 30-Jan-2018 Merger/Acquisition Discovery Tools (Healthcare)
To view Quanterix’s complete acquisitions history, request access »

Quanterix ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

23.96 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Quanterix’s complete esg history, request access »

Quanterix Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Emission Georgetown, TX 2020
UmanDiagnostics Umea, Sweden 2006

Quanterix FAQs

  • When was Quanterix founded?

    Quanterix was founded in 2007.

  • Where is Quanterix headquartered?

    Quanterix is headquartered in Billerica, MA.

  • What is the size of Quanterix?

    Quanterix has 450 total employees.

  • What industry is Quanterix in?

    Quanterix’s primary industry is Diagnostic Equipment.

  • Is Quanterix a private or public company?

    Quanterix is a Public company.

  • What is Quanterix’s stock symbol?

    The ticker symbol for Quanterix is QTRX.

  • What is the current stock price of Quanterix?

    As of 19-Nov-2026 the stock price of Quanterix is $2.03.

  • What is the current market cap of Quanterix?

    The current market capitalization of Quanterix is $96.4M.

  • What is Quanterix’s current revenue?

    The trailing twelve month revenue for Quanterix is $148M.

  • Who are Quanterix’s competitors?

    Seer, Revvity, Bio-Rad Laboratories, Siemens Healthineers, and Meridian Bioscience are some of the 9 competitors of Quanterix.

  • What is Quanterix’s annual earnings per share (EPS)?

    Quanterix’s EPS for 12 months was -$2.36.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process